RecruitingNCT05184400
Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer
Identification of New Biomarkers for Patients With Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) - do They Provide New Information Regarding Diagnosis, Treatment Efficacy, Side Effects, or Prognosis?
Sponsor
Herlev and Gentofte Hospital
Enrollment
500 participants
Start Date
Jan 1, 2015
Study Type
OBSERVATIONAL
Conditions
Summary
No validated biomarkers exist that can identify patients with biliary tract cancer at an early stage or predict treatment outcomes. The objective of the present study is to find diagnostic, prognostic and predictive biomarkers.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Histological or cytological diagnosis of BTC
- Patients referred for treatment of BTC
- Signed informed consent
Exclusion Criteria1
- None
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05184400
Related Trials
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
NCT066480571 location
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253168 locations
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT0692192817 locations
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
NCT046451601 location